BioSpace News Archive

Genetown

Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

Invivyd, Inc. (Nasdaq: IVVD) today announced the publication of research in the peer-reviewed journal Science Translational Medicine describing a model for evaluating biomarker correlates of protection for monoclonal antibodies (mAb) against symptomatic COVID-19.

March 22, 2023
·
9 min read
Business

SQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio Updates

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates.

March 22, 2023
·
7 min read
Drug Development

SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial.

March 22, 2023
·
7 min read
Business

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today reported its financial results for the year ended December 31, 2022 and provided a business update.

March 22, 2023
·
9 min read
Business

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter and full year ended December 31, 2022.

March 22, 2023
·
12 min read
FDA

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.

March 22, 2023
·
7 min read
ScreenPro Announces Management and Board Change

ScreenPro Security Inc. (CSE: SCRN) OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce the appointment of Alexander G. MacKay as its new Chief Executive Officer (CEO) and Chairman of the Company, effective March 23, 2023.

March 22, 2023
·
4 min read
Policy

Ionis announces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS

Ionis announced the outcome of the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with superoxide dismutase 1 amyotrophic lateral sclerosis.

March 22, 2023
·
6 min read